9th Annual Conference Focuses on Strategic Use of Data to Drive Corporate Knowledge Management Strategies
Guildford, UK, and Burlington, Mass., July 28, 2010 - IDBS, the leading worldwide provider of data management and analytics solutions to R&D and healthcare organizations, today announced that two of its customers, Genentech and Pfizer, will deliver keynote addresses at the IQPC 9th Annual ELNs and Advanced Laboratory Solutions conference in Amsterdam, September 27-29, 2010 - the leading conference for ELNs and data management strategies.
Dr. Martin Vanderlaan, Director of Analytical Operations at Genentech, will discuss how to harness user support for research excellence projects driven by the deployment of strategic informatics platforms. His presentation, "Genentech a Year On: Executing a Successful User Adoption Strategy to Prevent Project Delays," will highlight how designing a strong management plan, when implementing an ELN, is important to meeting the needs, expectations and training of users. A clear implementation strategy can promote thoughtful discussions within departments on organizational objectives, how they are being met and how users want to record their data, which can help standardize business processes within departments and ultimately drive ROI. He will describe the deployment at Genentech and how his organization leveraged end-user support to ensure a smooth rollout to 300 users in three months.
Mr. Jim King, Director of R&D Business Technology, Pfizer Diversified Businesses, will discuss how to create an enterprise strategy to drive the organization to a fully electronic environment. His presentation, "The Role of ELNs: A Chapter in a Much Larger Story," will highlight the importance of creating an enterprise strategy to build a seamless informatics platform and how to strategically select an ELN that fits with the overall company requirements. He will also recount the Wyeth/Pfizer GLP ELN deployment, including success factors and lessons learned.
In addition, Dr. Paul Denny-Gouldson, Product Manager at IDBS, will discuss the global management of R&D workflows using a true enterprise ELN. His session, "How ELNs Can Provide the Foundations to Leverage Corporate Knowledge," will illustrate how ELNs have evolved from merely capturing IP in a static format to becoming the foundation for data management, decision capture and analytics, in areas such as biopharma, biomarker discovery, bioanalysis, and preclinical formulations. In addition, Dr. Denny-Gouldson will discuss how only data management-driven ELNs can enable organizations to improve scientific collaboration and knowledge reuse.
"By maintaining close relationships with our customers, we provide the most relevant research data management solutions available in the market today. To be branded an IDBS solution, each must address the many needs of scientists, their organizations, collaborators and regulators," said Neil Kipling, founder and CEO of IDBS. "The E-WorkBook Suite now provides the leading data management and process improvement solution for preclinical and early drug development, and we are extremely pleased that two of our customers have been chosen to share the secrets of their success with their peer group at this year's conference."
IQPC's 9th Annual ELNs and Advanced Laboratory Solutions conference will be held September 27-29, at the Marriott Hotel, Amsterdam, The Netherlands. This year's event will deliver a host of new case studies and insight into how organizations are starting to integrate their ELNs into an overarching IT architecture. Attendees will learn how to establish a clear e-laboratory environment to increase their organizations' research efficiency, accelerate workflows, and enhance geo-separate collaboration.
Mr. King of Pfizer will present at 9:00am on Tuesday, September 28, and Dr. Vanderlaan of Genentech and Dr. Denny-Gouldson of IDBS will both speak on Wednesday, September 29, at 8:30am and 11:45am, respectively. For more information or to register for the conference, visit http://www.elnforum.com/Event.aspx?id=267434.
IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs and improve business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber, and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure, compliant capture, integration and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations' valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.
IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China.